9th Annual Biomarkers Congress

View Profile


Grant Support

Start year End year Title Source Position
1. 2009 Improvement of local control in locally advanced prostate cancer by combining the mTOR inhibitor Temsirolimus with ionizing radiation Wyeth Co-I
2. 2009 Effects of COX-2 inhibitors on pHi regulation in endothelial cells from different sources Pharmacia Co-investigator (Miriam Wahl, Ph.D., PI) effort 5%
3. 2009 RTOG Symposium on COX-2 Inhibitors and Cancer Therapeutics. Pharmacia, Aventis, Lilly and Merck Lead Organizer and Moderator
4. 2009 RTOG Symposium on Epidermal Growth Factor Receptor and Inhibitors and Cancer Therapeutics. Bristol Myers Squibb, AstraZeneca, Abgenix, Novartis, Wyeth Lead Organizer and Moderator
5. 2008 2009 Phase 1 study of the combination of Sorafenib and radiation therapy - /+ temozolomide for the treatment of patients with brain metastases and primary brain tumors. Bayer Heathcare Pharmaceuticals PI
6. 2006 2009 Nutrigenomics for the Study of Disease Prevention and Intervention USDA Coinvestigator
7. 2004 2009 R01-CA106633-01 Microenvironmental Control of the Radiation Response. National Cancer Institute PI, percent effort 25%
8. 2007 2008 A phase I, open label dose-escalation, safety, study of the combination of Sunitiniband radiation of the treatment of patients with cancer. Pfizer PI
9. 2007 2008 “Improvement of Tumor Control by BAY 43-9006” Bayer Pharmaceutical Coinvestigator
10. 2007 2008 Molecular Footprint of EGFR Inhibition in Human Hair follicles with a Focus on IL-1 Signaling BMS Co-PI
11. 2006 2008 Evaluation of Fullerene nanoparticles in a zebrafish model for drug discovery to mitigate the adverse effects of ionizing radiation. C Sixty Inc. PI (percent effort 5%)
12. 2006 2008 Characterization and Modulation of DNA Damage Response in Vertebrates using a Zebrafish Model Commonwealth Universal Research Enhancement (CURE) Program PI, percent effort 15%
13. 2005 2008 A phase I, open label dose-escalation, safety, study of the combination of bortezomib and chemoradiation of the treatment of patients with cancer. Millennium Pharmaceuticals PI
14. 1995 2008 Cancer Center Support Grant NCI, Translational Research in Cancer-2P30 CA05603-69 Program Leader-Radiation Research and Translational Biology 10% (Richard Pestell, PI)
15. 2006 2007 “Molecular determinants of glioblastoma response to ZD6474 combined with radiotherapy and temozolomide” AstraZeneca Coinvestigator
16. 2005 2007 Use of a zebrafish model for drug discovery to mitigate the adverse effects of radiation and chemotherapy used in the treatment of cancer. Mary Gilbert Trust PI (percent effort 5%)
17. 2005 2007 Microenvironmental Control of the Radiation Response after Erbitux Blockade: Development of a 3D model for Surrogate Markers and Response Imclone/BMS PI percent effort 10%
18. 2005 2007 Improvement of Colorectal Tumor Control by Combining Cetuximab with Radiotherapy and the Chemotherapeutic Agents, Oxaliplatin and Irinotecan (CPT-11). Imclone/BMS Co-I (Phyllis Wachsberger-PI), percent effort 5%
19. 2004 2007 2004 Summer Program in Basic Cancer Research. NCI R25 CA48010-14 Co-I (Ronald Coss-PI), percent effort 5%
20. 2001 2007 “Vice Chair-Translational Research Program, Radiation Therapy Oncology Program (RTOG)” NCI 5 U10 CA21661-31 20% (Walter Curran, PI)
21. 2005 2006 Improvement of Brain Tumor Control by Combining Cetuximab with Radiotherapy and the Chemotherapeutic Agent, Temozolamide. Imclone/BMS Co-I (Phyllis Wachsberger-PI), percent effort 5%
22. 2005 2006 Translational Studies on the Radiation Response in a Zebrafish Model Tobacco Settlement Act of Pennsylvania PI (percent effort 20%) Ulrich Rodeck-Co-I
23. 2003 2006 Biomarkers of prostate cancer response to radiation and hormone therapy Tobacco Settlement Act of Pennsylvania Co-Investigator, (Alan Pollack-PI), percent effort 10%
24. 2003 2006 Contrast-Enhanced Ultrasound Detection of Antiangiogenesis. National Cancer Institute Co-investigator (Flemming Forsberg, Ph.D., PI), effort 10%
25. 2004 2005 Effects of Chronic Oral Administration of a PARP inhibitor Alone and in Combination with ionizing radiation on Primary Tumor Growth in xenograft Models in nude mice. Cephalon Co-I (R. Burd-PI), percent effort 2.5%
26. 2004 2005 Molecular Signatures related to Amifostine radioprotection Mary Gilbert Trust PI (percent effort 5%)
27. 2004 2005 Optimization of EXEL, a Chk Inhibitor for Selective Sensitization of Tumor Cells to ionizing radiation. Exelixis Co-I, (R. Burd PI) percent effort 2.5%
28. 2004 2005 Improvement of Colorectal Tumor Control by Combining the Vascular Targeting Agent, ZD6474 with Radiotherapy and the Chemotherapeutic agents, Oxaliplatin and Irinotecan (CPT-11) AstraZeneca Co-PI, (Phyllis Wachsberger-PI), percent effort 5%
29. 2004 2005 Use of a novel vertebrate model to identify key genes functionally involved in the response to ionizing radiation. Virginia Logan Foundation PI (Mary Frances McAleer-Co-PI), percent effort 10%
30. 2003 2005 New Drug Development Program Core (NDDCPC) for the RTOG Tobacco Settlement Act of Pennsylvania PI (Randy Burd-Co-PI), percent effort 10%
31. 2002 2005 Improvement of Prostate Tumor Control by Combining Radiotherapy with an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase (ZD1839) and an Anti-Androgen Receptor Inhibitor (Bicalutamide) AstraZeneca Co-PI, (Phyllis Wachsberger-PI), percent effort 5%
32. 2004 2004 Evaluation of cell cycle genes in zebrafish. Virginia Logan Foundation Co-I (Mary Frances McAleer-PI), percent effort 5%
33. 2003 2004 Improvement of Tumor Control by Combining a Thrombospondin Mimetic, ABT-526, with Radiation Therapy Abbott Pharmaceuticals Co-PI, (Phyllis Wachsberger-PI), percent effort 5%
34. 2003 2004 Improvement of Prostate tumor control by combining radiotherapy with an inhibitor of epidermal growth factor receptor tyrosine kinase AstraZeneca Co-PI, (Phyllis Wachsberger-PI), percent effort 10%
35. 2003 2004 A Phase II Study of Bicalutamide (Casodex) 150 mg for prior to definitive management of localized adenocarcinoma of the prostate. AstraZeneca Principal investigator, percent effort 10%
36. 2003 2004 Validating NFkB as a Target for Prostate Cancer in RTOG 8610 Radiation Therapy Oncology Group Co-PI, (Christopher Sweeney-PI), percent effort 10%
37. 2003 2004 EO9 and Radiation Spectrum Pharmaceuticals Co-PI, (Randy Burd-PI), percent effort 5%
38. 2003 2004 Improvement of Cancer Therapy by Combining a VEGF Blocker, VEGF Trap, with Radiation Therapy Radiation Therapy Oncology Group Co-PI, (Phyllis Wachsberger-PI), percent effort 5%
39. 2002 2003 Molecular Genetic Analysis of Ductal Carcinoma In Situ Susan G. Komen Breast Cancer Foundation PI, percent effort 15% (initial PI-Bruce
40. 2002 2003 Enhancement of Tumor Response to Radiation by Use of Vascular Targeting Agent, ZD6126. PI: Phyllis Wachsberger, Ph.D AstraZeneca Co-PI, percent effort 2.5%
41. 2002 2003 Improvement of tumor control by combining an inhibitor of the epidermal growth factor receptor (EGFR) with Taxotere and Radiation therapy Aventis Corporation R. Burd, PI. Co-Principal Investigator, effort 5%
42. 2002 2003 Improving the therapeutic ratio by integrating metronomic sequencing of epirubicin and celecoxib with radiation therapy. Pharmacia Corporation Principal Investigator, 15% effort
43. 2002 2003 Improvement of Cancer Therapy by Combining Tie2 Receptor Tyrosine Kinase Inhibitors with Ionizing Radiation Radiation Therapy Oncology Group Co-PI, (Phyllis Wachsberger-PI) percent effort 5%
44. 2002 2003 Improvement of Taxotere Penetration in Solid Tumors and Improvement in Tumor Oxygenation using an Anti-Platelet Agent During Fractionated Radiotherapy. K. Sidhu, PI Radiation Therapy Oncology Group Co-PI, percent effort 15%
45. 1998 2003 The science of DNA damage response NCI Preceptor
46. 2001 2002 Simultaneous inhibition of Cyclooxygenase-2 (COX-2) and Epidermal growth factor receptor (EGFR) in combination with ionizing radiation. Radiation Therapy Oncology Group Principal Investigator
47. 2000 2002 Improving the therapeutic ratio by integrating inhibitors of angiogenesis with radiation therapy. : EntreMed Corp. Principal Investigator
48. 2000 2002 Evaluation of ultrasound images during prostate brachytherapy Nycomed/Amersham Corporation Principal Investigator
49. 2000 2001 Evaluation of extraprostatic coverage of permanent radioactive seed implants.s Nycomed/Amersham Principal Investigator
50. 2000 2001 Effects of anti-angiogenic agents on pHi regulation in endothelial cells from different sources Jefferson Medical College Co-investigator
51. 2000 2001 Improving the therapeutic ratio by integrating inhibitors of COX-2 with radiation therapy. Merck Research Labs
52. 2000 2001 Use of alpha-blockers after symptoms after prostate brachytherapy. Boehringer Ingelheim Principal Investigator
53. 2000 2001 Inhibition of angiogenesis and radiation therapy. Magainin Pharmaceuticals Principal Investigator
54. 2000 2000 Evaluation of modified permanent seeds in a dog prostate model. Nycomed/Amersham Principal Investigator
55. 1999 2000 Evaluation of parameters of neovascularity in brain tumor specimens of patients enrolled in RTOG trial 98-06 - A phase II study of conventional radiation therapy plus thalidomide for supratentorial glioblastoma. Radiation Therapy Oncology Group Foundation Principal Investigator
56. 1999 2000 Targeting angiogenesis by paclitaxel. Dean, Jefferson Medical College Principal Investigator
57. 1999 2000 Fellowship program in prostate brachytherapy. Ethicon Endo-Surgery Inc, Urology Principal Investigator
58. 1999 1999 Understanding the urinary symptoms after prostate brachytherapy Boehringer Ingelheim Principal Investigator
59. 1999 1999 Use of hormonal therapy in prostate brachytherapy. AstraZeneca Principal Investigator
60. 1999 1999 Are urinary symptoms related to urethral dose? Bard Urologic Principal Investigator
61. 1998 1998 How should the urinary symptoms after prostate brachytherapy be measured? The strength and weaknesses of the AUA, RTOG-GU, and NCI Common Toxicity Criteria. Bard Urologic medical student
62. 1997 1998 Combined modality treatment: p53 status and paclitaxel radiosensitivity M. L. Smith Charitable Lead Trust Principal Investigator
63. 1997 1998 Paclitaxel and its interaction with radiation. Foerderer Foundation Principal Investigator


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.